Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Amgen | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Amgen

Growth in the quarter was driven by Prolia, up 15%

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Amgen
2Q Revenues:  $5.8 billion (+2%)
2Q Earnings: $2.2 billion (+15%)
YTD Revenues: $11.3 billion (flat)
YTD Earnings: $4.2 billion (+12%)
Comments: Growth in the quarter was driven by Prolia, up 15% to $505 million, Repatha sales of $83 million, and KYPROLIS sales were up 23% to $211 million, helping to offset losses for Neulasta (down 5% to $1.1 billion), NEUPOGEN (down 30% to $137 million), and EPOGEN sales (down 12% to $292 million). BLINCYTO sales increased 43% to $43 million. Sensipar / Mimpara sale were up 10% to $427 million. Enbrel sales were $1.5 billion, up 1%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters